Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Objective: Few tumor-associated, immunogenic epitopes are available for antitumor vaccinations in SCCHN. Our antigen discovery program identified an aldehyde dehydrogenase 1 family member A1 (ALDH1A1) as a source of a CD8+ T-cell–defined HLA-A2–restricted peptide ALDH1A188-96 (LLYKL ADLI).
Methods: In vitro sensitization (IVS) of HLA-A2+ normal or patients' peripheral blood mononuclear cells (PBMCs) with peptide-pulsed dendritic cells was used to generate T-cell lines that were specific for ALDH1A1 peptides. We studied peptide messenger RNA expression, tumor specificity, and localization in tissues of the source protein using immunohistochemistry and Western blotting. Cytolytic T-lymphocyte (CTL) activity against squamous cell carcinoma of the head and neck (SCCHN) was tested in ELISPOT and cytotoxicity assays. Tetramers were used to assess the frequency of peptide-specific T cells in patients' PBMCs. Enzymatic activity was measured using Aldefluor by flow cytometry.
Visus C, Whiteside TL, DeLeo AB. S003 Identification of a Novel HLA-A*0201–Restricted T-Cell–Defined Antigen in Human SCCHN. Arch Otolaryngol Head Neck Surg. 2006;132(8):838. doi:10.1001/archotol.132.8.838-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: